Letter from the Editor

Contributed by:

Taren Grom, Editor

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

On Tap for 2017

PV0315_TarenGromAs this issue was going to press, the next president of the United States was still being hotly contested. But no matter if the blue states or red states prevail, the state of the pharmaceutical industry will be impacted. According to a Smith Hanley Associates report, polls found that high drug costs are the No. 1 healthcare priority of Americans, eclipsing Obamacare, even among Republicans and independents.
Further, a tracking poll by the Kaiser Family Foundation found that almost two-thirds of Americans supported “government action to lower prescription drug prices.”

In response to this public pressure, both presidential candidates’ platforms include initiatives that will significantly affect the pharmaceutical industry no matter who is elected. While it may not be apparent from the seemingly never-ending rhetoric of this political season, both candidates are espousing several similar changes that will impact the business of pharma, including increased price transparency, changes to Medicare, and changes to the restrictions on foreign and generic drug importation.

In the coming months and years to come, change is coming. Novartis CEO Joe Jimenez summed up the state of the pharma union quite concisely: “We believe that, no matter which candidate wins, we will see a more difficult pricing environment in the U.S. We all have to plan for new pricing models in the U.S. that could help us ensure the sustainability of the system as the population ages.”

The election is not the only market driver that we expect will have a significant impact on the industry in 2017 and beyond.
PharmaVOICE is once again excited to share the top 10 trends that are anticipated to affect both near-term and long-term business strategies. These top 10 trends are presented in alpha order by subject, and are not intended to be a ranking as we believe each trend carries significant weight in terms of disruption of the status quo. Interestingly, as we delved into this issue we found a couple of common threads that weave these trends together. Without doubt it’s technology — in all forms — that is the biggest common denominator. From smart technologies to health bots to gene editing tools, to new ways to engage workforce talent, technological disruption is the new normal. The question is: can pharma keep up?

More than 150 thought leaders featured in this special issue not only answer this question but provide their insights on our 10 trends: the Cancer Moonshot, Combination Products, Gene Editing, Health Bots, the Industrial Internet, Precision Medicine, Smart Technologies, Talent War, Triple Aim, and Virtual Reality.

We also recognize that this short list is in no way exhaustive and that there are other mega and micro trends that will continue to emerge in the days and months ahead. We encourage you to send us your thoughts for inclusion in a future issue. Please shoot me an email at

Finally, wishing you a happy and prosperous 2017, and get ready for a wild ride.

Taren Grom, Editor


pv1116_theirwordTheir Word…

Denise Myshko
Managing Editor

Newer gene editing tools are leading to excitement about the possibilities for treating diseases in the future.

Robin Robinson
Senior Editor

Health bots, smart technology, and virtual reality are just a few of the tools shaping a new future in innovation for the life-sciences industry.

Kim Ribbink
Features Editor

Smart technology, digitization, along with some exciting new scientific advances, have been the hallmark of 2016.


Coming in January 2017

Follow the Money: Where VCs are Putting Their Money
Content Marketing Trends
Organs on Chips
Global Expedited Review
Disease State: HIV
Rare Diseases: R&D
Showcase: Social Media



Volume 16 • Number 10
Publisher    Lisa Banket
Editor    Taren Grom
Creative Director    Marah Walsh

Managing Editor
Denise Myshko

Senior Editor
Robin Robinson

Features Editor
Kim Ribbink

Design Associate
Ariel Medel

Director of Sales
Cathy Tracy

National Account Manager
Suzanne Besse

Webcast Network Producer
Daniel Limbach

Circulation Assistant
Kathy Deiuliis

Copyright 2016
by PharmaLinx LLC, Titusville, NJ
Printed in the U.S.A.
Volume Sixteen, Number Ten

PharmaVoice (ISSN: 1932961X) is published monthly except joint issues in July/Aug. and Nov./Dec., by ­Pharma­­Linx LLC, P.O. Box 327, Titusville, NJ 08560. ­Periodicals postage paid at Titusville, NJ 08560 and additional mailing offices.

Postmaster: Send address changes to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345.

PharmaVoice Coverage and Distribution:
Domestic subscriptions are available at $190 for one year (10 issues). Foreign subscriptions: 10 issues US$360. Contact PharmaVoice at P.O. Box 327, Titusville, NJ 08560. Call us at 609.730.0196 or FAX your order to 609.730.0197.

Contributions: PharmaVoice is not responsible for unsolicited contributions of any type. Unless otherwise agreed in writing, PharmaVoice retains all rights on material published in PharmaVoice for a period of six months after publication and reprint rights after that period expires. E-mail: tgrom@pharmavoice.com.

Change of address: Please allow six weeks for a change of address. Send your new address along with your subscription label to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345. Call us at 800.607.4410 or FAX your change to 937.890.0221. E-mail: mwalsh@pharmavoice.com.

Important notice: The post office will not forward copies of this magazine. PharmaVoice is not responsible for replacing undelivered copies due to lack of or late notification of address change.

Advertising in PharmaVoice: To advertise in Pharma­­Voice please contact our Advertising ­Department at P.O. Box 327, Titusville, NJ 08560, or ­telephone us at 609.730.0196. E-mail: lbanket@pharmavoice.com.

Posted in:

Post a Comment

You must be logged in to post a Comment.